Keytruda is not only Merck & Co.’s top product but also one of the best-selling drugs worldwide, generating over 25 billion U.S. dollars in revenue during 2025. The cancer drug with the generic name pembrolizumab increased its revenues for around four billion U.S. dollars compared to 2022.
Revenue of Keytruda from 2014 to 2023
(in million U.S. dollars)
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Merck & Co.. (February 26, 2024). Revenue of Keytruda from 2014 to 2023 (in million U.S. dollars) [Graph]. In Statista. Retrieved December 23, 2024, from https://www.statista.com/statistics/1269401/revenues-of-keytruda/
Merck & Co.. "Revenue of Keytruda from 2014 to 2023 (in million U.S. dollars)." Chart. February 26, 2024. Statista. Accessed December 23, 2024. https://www.statista.com/statistics/1269401/revenues-of-keytruda/
Merck & Co.. (2024). Revenue of Keytruda from 2014 to 2023 (in million U.S. dollars). Statista. Statista Inc.. Accessed: December 23, 2024. https://www.statista.com/statistics/1269401/revenues-of-keytruda/
Merck & Co.. "Revenue of Keytruda from 2014 to 2023 (in Million U.S. Dollars)." Statista, Statista Inc., 26 Feb 2024, https://www.statista.com/statistics/1269401/revenues-of-keytruda/
Merck & Co., Revenue of Keytruda from 2014 to 2023 (in million U.S. dollars) Statista, https://www.statista.com/statistics/1269401/revenues-of-keytruda/ (last visited December 23, 2024)
Revenue of Keytruda from 2014 to 2023 (in million U.S. dollars) [Graph], Merck & Co., February 26, 2024. [Online]. Available: https://www.statista.com/statistics/1269401/revenues-of-keytruda/
